We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Jadestone Energy Plc | LSE:JSE | London | Ordinary Share | GB00BLR71299 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 1.00% | 25.25 | 25.00 | 25.50 | 25.25 | 25.25 | 25.25 | 906,433 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Crude Petroleum & Natural Gs | 323.28M | -91.27M | -0.1688 | -1.50 | 135.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/5/2024 16:01 | Take care, wishing you a full recovery... | neo26 | |
20/5/2024 15:11 | I had one of those calls last year. | 34adsaddsa | |
20/5/2024 14:46 | I haven't received any call and I've got quite a few (high 6 figure, significantly under water. ahem) so interesting cm2. | dunderheed | |
20/5/2024 14:41 | I haven't yet seen the resolutions being proposed at the AGM but have just received a telephone call from EQ Proxy on behalf of Jadestone asking about my voting intentions. I assume management are concerned about something. Any ideas what? | chessman2 | |
20/5/2024 14:16 | Very best of luck and strength to you MT. If anyone can beat this it is someone like you mate!! Stay strong!! Dunders. | dunderheed | |
20/5/2024 14:04 | Health Update - received some unwelcome news today, the latest PT Scan has revealed my formidable foe (Metastatic Melanoma) has returned with a vengeance - again targeting the Lymph Node system. Just my luck! Clearly worked out from our first fight that its up against an opponent that enjoys a good challenge.......and so has returned in a better trained condition for a sequel! However, I too am much better prepared and, will be entering the ring the second time around three stone heavier and much fitter and stronger. Should be a good match up! The revised treatment plan will consist of a combination of immunotherapy and radiotherapy, with 6-8 week PET Scans(score cards to measure our performances). | mount teide | |
20/5/2024 14:00 | Tight with no leaks! | officerdigby | |
20/5/2024 13:58 | I've been out of JSE for ages but now it's interesting me again.. I agree with many others here it's very cheap. It just needs to show it can run a tight ship again. | celeritas | |
20/5/2024 09:23 | I agree, jse is cheap.It should never have fallen under 30p even with montara issue, they have diversified their assets. Montara is now 25% of production. Almost all capex for Akatara should be near the end. Jse is going to be generating serious cash. | neo26 | |
19/5/2024 12:29 | neo26 - at a £155m market cap - based on the fundamentals, strongly suspect investors(as opposed to traders), are likely to consider such a scenario, were it to occur, as a buying opportunity. Took advantage of a similar situation last summer at Afentra, while waiting for completion of three acquisitions to reduce my average price to 25.8p - the stock is now trading at 53.5p. Even the best traders with perfect timing shorting Afentra during that period could have only scalped a max of circa 20%. While buy and hold investors who bought the pullback are since up CIRCA 130-150%, on a stock with fundamentals that are now almost certainly better than last summer, such has been the production growth from the two deals they've since closed......combined with the huge financial benefit they generated from the effective economic date of the deals(and soon to be completed third deal), at an average $85/bbl oil price while they awaited completion. Have a number of other holdings, some of which were mentioned here, where similar share-price pullbacks delivered 'value' buying opportunities for investors who had carried out the research and could see the bigger, longer term growth picture. With first production imminent from Akatara, and Montara Venture's regulatory issues under effective control, posted recently that I now consider JSE to be in the same category.....ie - a 'Value' investment. AIMHO/DYOR | mount teide | |
18/5/2024 20:28 | Any delays from akatara this will take a hit. Im guessing a few weeks delay. | neo26 | |
17/5/2024 13:35 | Short clip ten days ago akatara..Not sure when actually filmed though | sea7 | |
17/5/2024 07:49 | Somebody is. He bought that share. . | fardels bear | |
16/5/2024 12:28 | I’m going to my first JSE AGM this year. Is anyone else going? | tim000 | |
14/5/2024 22:35 | Perhaps, but I still think it is a good sign that I can't place a buy spread bet, albeit that it's annoying. | puzzler2 | |
14/5/2024 21:04 | Yes, but they can set very small in house limits also. Might simply be that they felt too much risk on JSE. Certainly puzzler is incorrect in his post. | nigelpm | |
14/5/2024 16:19 | Which is like their customers having a view | fardels bear | |
14/5/2024 12:50 | They haven't accepted any since it came back from Suspension. I even had to inform them to reduce margin from 100% down again. It's very rarely because they have a view on the stock FWIW - almost certainly that their broker has hit certain limits | nigelpm | |
14/5/2024 09:55 | IG.com today are not accepting spreadbet buy orders on JSE - presumably they believe a) the odds of it going up are greater than it going down; or b) they are already as exposed as they want to be on buy spreadbets. Either way, a positive sign imo. | puzzler2 | |
14/5/2024 07:05 | I think it would be more true to say that they step in it everywhere | fardels bear | |
13/5/2024 12:05 | The thing about permabulls is they always try to walk it in. | arlington chetwynd talbott | |
12/5/2024 22:00 | Thank you for that - I take your point. | arlington chetwynd talbott | |
12/5/2024 14:31 | The thing with permabears is that they've called eleven of the last three recessions. | nk104 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions